Immunisation of koalas against Chlamydia pecorum results in significant protection against chlamydial disease and mortality.

IF 6.9 1区 医学 Q1 IMMUNOLOGY NPJ Vaccines Pub Date : 2024-08-06 DOI:10.1038/s41541-024-00938-5
Samuel Phillips, Jon Hanger, Julien Grosmaire, Ahmed Mehdi, Martina Jelocnik, Jessie Wong, Peter Timms
{"title":"Immunisation of koalas against Chlamydia pecorum results in significant protection against chlamydial disease and mortality.","authors":"Samuel Phillips, Jon Hanger, Julien Grosmaire, Ahmed Mehdi, Martina Jelocnik, Jessie Wong, Peter Timms","doi":"10.1038/s41541-024-00938-5","DOIUrl":null,"url":null,"abstract":"<p><p>In 2022, the Australian Government listed the koala as endangered in several states due to habitat destruction, traffic strikes, dog attacks, and Chlamydia pecorum disease. This study evaluates a 10-year assessment of a Major Outer Membrane Protein-based vaccine's effectiveness against chlamydial disease in wild koalas from Southeast Queensland. Over a decade, 680 koalas were tracked, with five vaccine trials involving 165 koalas. While prior studies only offered up to two years of data, this study's extended period allowed a thorough evaluation of vaccine efficacy. Results showed that vaccinated koalas had significantly lower disease incidence, with a 64% reduction in chlamydial mortality. This vaccine demonstrated positive impacts on both male and female koalas, highlighting its crucial role in conserving the Australian koala population and mitigating the threats they face.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"139"},"PeriodicalIF":6.9000,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303382/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-024-00938-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In 2022, the Australian Government listed the koala as endangered in several states due to habitat destruction, traffic strikes, dog attacks, and Chlamydia pecorum disease. This study evaluates a 10-year assessment of a Major Outer Membrane Protein-based vaccine's effectiveness against chlamydial disease in wild koalas from Southeast Queensland. Over a decade, 680 koalas were tracked, with five vaccine trials involving 165 koalas. While prior studies only offered up to two years of data, this study's extended period allowed a thorough evaluation of vaccine efficacy. Results showed that vaccinated koalas had significantly lower disease incidence, with a 64% reduction in chlamydial mortality. This vaccine demonstrated positive impacts on both male and female koalas, highlighting its crucial role in conserving the Australian koala population and mitigating the threats they face.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对考拉进行啄木鸟衣原体免疫接种可显著预防衣原体疾病和死亡率。
2022 年,由于栖息地遭到破坏、交通事故、狗的袭击以及啄木鸟衣原体疾病,澳大利亚政府将多个州的考拉列为濒危物种。本研究评估了一种基于主要外膜蛋白质的疫苗在昆士兰东南部野生考拉中预防衣原体疾病的十年效果。十年间,共对 680 只考拉进行了跟踪调查,其中五次疫苗试验涉及 165 只考拉。以前的研究最多只能提供两年的数据,而这项研究延长了时间,可以对疫苗的功效进行全面评估。结果显示,接种疫苗的考拉发病率明显降低,衣原体死亡率降低了 64%。这种疫苗对雄性和雌性考拉都产生了积极影响,凸显了它在保护澳大利亚考拉种群和减轻它们面临的威胁方面的重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
NPJ Vaccines
NPJ Vaccines Immunology and Microbiology-Immunology
CiteScore
11.90
自引率
4.30%
发文量
146
审稿时长
11 weeks
期刊介绍: Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.
期刊最新文献
The PvRBP2b-TfR1 interaction is not essential for reticulocytes invasion by Plasmodium vivax isolates from Cambodia. Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity. MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates. Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine. Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1